- Home
- ABUS vs IIIV Comparison
ABUS vs IIIV Comparison
Compare ABUS & IIIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABUS
- IIIV
- Stock Information
- Founded
- ABUS N/A
- IIIV 2012
- Country
- ABUS United States
- IIIV United States
- Employees
- ABUS N/A
- IIIV N/A
- Industry
- ABUS Biotechnology: Pharmaceutical Preparations
- IIIV EDP Services
- Sector
- ABUS Health Care
- IIIV Technology
- Exchange
- ABUS Nasdaq
- IIIV Nasdaq
- Market Cap
- ABUS 636.2M
- IIIV 570.8M
- IPO Year
- ABUS N/A
- IIIV 2018
- Fundamental
- Price
- ABUS $3.06
- IIIV $23.62
- Analyst Decision
- ABUS Strong Buy
- IIIV Buy
- Analyst Count
- ABUS 4
- IIIV 7
- Target Price
- ABUS $5.50
- IIIV $29.86
- AVG Volume (30 Days)
- ABUS 997.4K
- IIIV 227.3K
- Earning Date
- ABUS 05-01-2025
- IIIV 02-06-2025
- Dividend Yield
- ABUS N/A
- IIIV N/A
- EPS Growth
- ABUS N/A
- IIIV 21740.15
- EPS
- ABUS N/A
- IIIV 4.87
- Revenue
- ABUS $6,742,000.00
- IIIV $236,560,000.00
- Revenue This Year
- ABUS N/A
- IIIV $12.59
- Revenue Next Year
- ABUS N/A
- IIIV $8.24
- P/E Ratio
- ABUS N/A
- IIIV $4.90
- Revenue Growth
- ABUS N/A
- IIIV 20.85
- 52 Week Low
- ABUS $2.30
- IIIV $18.75
- 52 Week High
- ABUS $4.72
- IIIV $29.80
- Technical
- Relative Strength Index (RSI)
- ABUS 34.37
- IIIV 33.25
- Support Level
- ABUS $3.32
- IIIV $23.97
- Resistance Level
- ABUS $3.55
- IIIV $25.60
- Average True Range (ATR)
- ABUS 0.17
- IIIV 1.29
- MACD
- ABUS -0.04
- IIIV -0.45
- Stochastic Oscillator
- ABUS 5.88
- IIIV 2.88
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.
About IIIV i3 Verticals Inc.
i3 Verticals Inc offers integrated payment and software solutions to small and medium-sized businesses and organizations in strategic vertical markets. Its operating segment includes Public Sector and Healthcare. The company generates maximum revenue from the Public Sector segment.